GSK Ends Deal For Anacor’s Antibiotic, Returns Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.